Table 1 Characteristics of studies included in the systematic review
From: SARS-CoV-2 vaccine breakthrough infection in the older adults: a meta-analysis and systematic review
Study ID | Country | Study type | Vaccine type and dose | study period | age range | sample size | outcome |
|---|---|---|---|---|---|---|---|
Barak Mizrahi 2021.11 [12] | Israel | retrospective cohort study | the BNT162b2-2dose | 2021.6.1–2021.7.27 |  > 60 | 55,512 | 1a |
LaithJ.Abu-Raddad 2021.11 [13] | Qatar | retrospective cohort study | the BNT162b2-2dose mRNA-1273-2dose | 2020.12.21–2021.9.19 |  > 60 | 67,808 | 1 |
Aharona Glatman-Freedman 2021.10 [14] | Israel | retrospective cohort study | the BNT162b3-1 or 2dose | 2020.12.21–2021.2.6 |  > 60 | NA | 12b3c4d5e |
Matthew W Reynolds 2022.9 [15] | USA | Cross-Sectional study | BioNTech-2dose Moderna-2dose Ad26.COV2.S-1dose | 2020.12.15–2021.9.16 |  > 60 | 2436 | 1 |
Jose-Miguel Yamal 2022.5 [16] | USA | Cross-Sectional study | BioNTech-2dose Moderna-2dose Ad26.COV2.S-1dose | 2020.12.14–2021.9.30 |  > 60 | NAf | 1 |
Yinon M. Bar-ON 2022.4 [17] | Israel | retrospective cohort study | the BNT162b2-3 or 4dose | 2022.1.10–2022.3.2 |  > 60 | 1,252,331 | 14 |
Sara Y Tartof 2021.10 [6] | USA | retrospective cohort study | the BNT162b2-1dose | 2020.12.14–2021.8.8 |  > 65 | 8923 | 13 |
Utkarsh Agrawal 2021.12 [18] | Scotland | prospective cohort study | ChAdOx1-1dose the BNT162b3-1dose | 2020.12.8–2021.4.18 |  > 65 | 912,348 | 3 or 5 |
Eli S. Rosenberg 2021.12 [19] | USA | retrospective cohort study | the BNT162b3-NA Mrna-1273-NA Ad26.COV2.S-NA | 2021.5.1–2021.9.3 |  > 65 | 2,088,491 | 13 |
Ori Magen 2022.4 [20] | Israel | retrospective cohort study | the BNT162b3-3 or four dose | 2022.1.3–2022.2.18 |  > 60 | 364,244 | 12,345 |
Veerle Stouten 2022.4 [21] | Belgium | Cross-Sectional study | BNT162b2 -2 dose mRNA-1273–2 dose ChAdOx1-2 dose Ad26.COV2.S-1dose | 2021.2.1–2021.6.18 |  > 65 | 2,105,175 | 12 |
Amelia Green 2022.7 [22] | England | Cross-Sectional study | BNT162b2 -2dose ChAdOx1 nCoV-19-2dose mRNA-1273-2dose | 2020.12–2021.11 |  > 60 | 5,583,760 | 1345 |
J. Daniel Kelly2022.9 [23] | USA | retrospective cohort study | BNT162b2 -3 dose mRNA-1273–3 dose Ad26.COV2.S-2 dose | 2021.7.1–2022.5.30 |  > 65 | 1,100,248 | 2 3or5 |
Nina Breinholt Stærke 2022.8 [24] | Denmark | Cross-Sectional study | BNT162b2 -2 dose mRNA-1273-2dose ChAdOx1-1 dose | 2021.7.1—2022.2.1 |  > 65 | 2918 | 1 |
Eric J Haas 2021.5 [25] | Israel | retrospective cohort study | the BNT162b3-2dose | 2021.1.24–2021.4.3 |  > 65 | 1,015,620 | 12,345 |
Karin Hardt 2022.9 [26] | Belgium, Brazil Colombia France Germany the Philippines South Africa Spain the UK the USA | Randomized controlled Trail | Ad26.COV2.S -2 dose | 2020.11.16–2021.6.25 |  > 60 | 1894 | 4 |
Jerald Sadoff 2022.2 [27] | Argentina Brazil, Chile Colombia, Mexico Peru South Africa The United States | Randomized controlled Trail | Ad26.COV2.S-1dose | 2020.9.21—2021.7.9 |  > 60 | 6735 | 4 |
Raches Ella 2021.12 [28] | Indian | Randomized controlled Trail | BBV152-2 dose | 2020.11.16–2021.5.17 |  > 60 | 893 | 2 |
Hana M El Sahly 2021.11 [29] | USA | Randomized controlled Trail | mRNA-1273-2dose | 2020.10.23–2021.3.26 |  > 65 | 3626 | 2 |
scott A Halperin 2022.1 [30] | Argentina, Chile, Mexico Pakistan Russia | Randomized controlled Trail | The Ad5-nCoV vaccine-1 dose | 2020.9.22.–2021.1.15 |  > 60 | 1323 | 24 |
Ann R. Falsey 2021.12 [31] | the United States Chile, Peru | Randomized controlled Trail | ChAdOx1 nCoV-19–2 dose | 2020.8.28–2021.3.5 |  > 65 | 4827 | 2 |
Giulia Vivaldi 2022.11 [32] | UK | prospective cohort study | ChAdOx1 nCoV-19-2dose BNT162b2 -3 or 4dose mRNA-1273–4 dose | 2020.5.1–2022.2.21 |  > 60 | 15,777 | 1 |
Alejandro Jara 2021.7 [33] | Chile | prospective cohort study | CoronaVac-2 dose | 2021.2.2–2021.5.1 |  > 60 | 2,230,270 | 1345 |
Sharon Hui Xuan Tan 2022.2 [34] | Singapore | retrospective cohort study | the BNT162b2-2dose the mRNA1273-2dose | 2021.9.15–2021.10.31 |  > 60 | 127,077 | 14 |
Jennifer M. Polinski 2022.3 [35] | US | cohort study | Ad26.COV2.S-1dose | 2020.3.1–2021.8.31 |  > 65 | 125,402 | 13 |
Tyler N. A. Winkelman 2022.3 [36] | USA | cohort study | the BNT162b2-2dose Mrna1273-2dose Ad26.COV2.S-1dose | 2020.10.25–2021.10.30 |  > 65 | 780,723 | 3 |
Massimo Fabiani 2022.2 [37] | Italy | retrospective cohort study | the BNT162b2-2dose Mrna1273-2dose | 2020.12.27–2021.11.7 |  > 65 | 10,485,794 | 1 3or5 |
Julia Hippisley-Cox 2021.9 [38] | UK | prospective cohort study | the BNT162b2-1 or 2dose ChAdOx1nCoV-19–1 or 2dose | 2020.12.8–2021.6.15 |  > 65 | 2,454,586 | 35 |
Peter Nordstrom 2022.3 [39] | Sweden | cohort study | the BNT162b2-2dose Mrna1273-2dose ChAdOx1nCoV-19-2dose | 2021.1.12—2021.10.4 |  > 65 | NA | 1 |
Srinivasa Vittal Katikireddi 2022.1 [40] | Scotland | Retrospective cohort study | ChAdOx1nCoV-19-2dose | 2021.1.18–2021.10.25 |  > 65 | 5,463,138 | 2 3or5 |